Search results

  1. forestglip

    Evidence of White Matter Neuroinflammation in [ME/CFS]: A Diffusion-Based Neuroinflammation Imaging Study 2026 Yu et al

    We just did force it to happen. In the updated code I posted, in 92% of the trials where niiXX was not significantly associated with ME/CFS status (analogous to them showing no association for the univariate test in the paper), adding a covariate made it a significant association (significant...
  2. forestglip

    Evidence of White Matter Neuroinflammation in [ME/CFS]: A Diffusion-Based Neuroinflammation Imaging Study 2026 Yu et al

    This is because in the model you made, there is no relationship between ME/CFS and niXX, so it is all due to chance. niXX is just a function of age, so there should only be about 5% significant as false positives when testing the association with mecfs_status. If niXX actually depends on...
  3. forestglip

    Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

    Several posts about Sjogren's were moved to: Is there a connection between ME/CFS and Sjogren's Syndrome? Discussion and a poll about testing
  4. forestglip

    Evidence of White Matter Neuroinflammation in [ME/CFS]: A Diffusion-Based Neuroinflammation Imaging Study 2026 Yu et al

    You replaced model1 <- lm(niirf ~ 1) with model1 <- lm(niirf ~ 0). 1 is the formula for an intercept. 0 means no intercept. From the R docs: So in the first updated code you posted, in the comparison of model1 and model2, it's comparing a model that just predicts 0 for every point with a...
  5. forestglip

    Evidence of White Matter Neuroinflammation in [ME/CFS]: A Diffusion-Based Neuroinflammation Imaging Study 2026 Yu et al

    Here is some R code simulating this with random data where NII-RF is correlated to age and to ME/CFS status: Output: To get an idea of what the p-values are, I looked at the ANOVA results for the last trial: When comparing the models without age, the p-value was 0.48. With age, it was 0.03.
  6. forestglip

    Evidence of White Matter Neuroinflammation in [ME/CFS]: A Diffusion-Based Neuroinflammation Imaging Study 2026 Yu et al

    In the case of models 3 and 4, we can be more confident about the amount that ME/CFS status improves the model, since the age variable is included and can explain some of the variance. I'm not able to right now, but I might code it with simulated data later. It should be relatively...
  7. forestglip

    Evidence of White Matter Neuroinflammation in [ME/CFS]: A Diffusion-Based Neuroinflammation Imaging Study 2026 Yu et al

    I'm not sure what exactly you mean by the p-value of the initial model. The p-value of the ME/CFS status coefficient in a model including all covariates? I think this is the same p-value you would get from an F-test comparing the model with and without ME/CFS status.
  8. forestglip

    Evidence of White Matter Neuroinflammation in [ME/CFS]: A Diffusion-Based Neuroinflammation Imaging Study 2026 Yu et al

    Yes, but this is in the case of age being correlated to both ME/CFS status and NII-RF. Age can be correlated to only NII-RF, in which case adding this variable to a model that only had ME/CFS does lead to better predictive ability for NII-RF.
  9. forestglip

    Evidence of White Matter Neuroinflammation in [ME/CFS]: A Diffusion-Based Neuroinflammation Imaging Study 2026 Yu et al

    Yeah, decreased standard error for the coefficient of the main exposure on the outcome since some of the noise is accounted for by the covariate. Edit: This goes a bit into it, talking about how controlling for covariates increases precision...
  10. forestglip

    Evidence of White Matter Neuroinflammation in [ME/CFS]: A Diffusion-Based Neuroinflammation Imaging Study 2026 Yu et al

    I also wasn't sure why it would be necessary to match group size. Are they saying they excluded ME/CFS participants that didn't have similar metrics to a healthy control? Or they just randomly removed ME/CFS participants to match group size? Either way, I don't really see the reason for doing...
  11. forestglip

    Evidence of White Matter Neuroinflammation in [ME/CFS]: A Diffusion-Based Neuroinflammation Imaging Study 2026 Yu et al

    I don't think it's an issue. Often significance decreases after controlling for a variable because a covariate is correlated to both the exposure and the outcome, so it explains part of the relationship. But significance can increase if controlling for a covariate that is mainly correlated to...
  12. forestglip

    Miscellaneous Research Thread

    A gain-of-function Retsat variant from high-altitude adaptation promotes myelination via a neuronal dihydroretinoic acid-RXR-γ pathway, 2026, Li et al A gain-of-function Retsat variant from high-altitude adaptation promotes myelination via a neuronal dihydroretinoic acid-RXR-γ pathway...
  13. forestglip

    Cross-ancestry genetic architecture reveals shared biological pathways of major psychiatric disorders, 2026, Feng et al

    Here is the VRK2 variant they highlighted in the text, rs7596038 (2-58156685-C-T), highlighted over the DecodeME data: It doesn't look to be within the main ME/CFS locus. Though it's interesting that there are two loci with somewhat significant lead variants in ME/CFS around this area. Maybe...
  14. forestglip

    Cross-ancestry genetic architecture reveals shared biological pathways of major psychiatric disorders, 2026, Feng et al

    NEGR1 was at the 10th most significant locus and VRK2 was at the 25th most significant locus in DecodeME. The loci plots can be seen in this post...
  15. forestglip

    Cross-ancestry genetic architecture reveals shared biological pathways of major psychiatric disorders, 2026, Feng et al

    Cross-ancestry genetic architecture reveals shared biological pathways of major psychiatric disorders Abstract Psychiatric disorders, including bipolar disorder (BD), major depressive disorder (MDD), and schizophrenia (SCZ), share substantial genetic overlap. We conducted a cross-ancestry...
  16. forestglip

    Review Molecular hydrogen as a treatment for ME/CFS: a mini-review of clinical evidence and mechanistic rationale, 2026, Friedberg et al

    Similarly titled paper from a few years ago: Molecular Hydrogen as a Medical Gas for the Treatment of Myalgic Encephalomyelitis/CFS: Possible Efficacy Based on a Literature Review, 2022, Hirano
  17. forestglip

    Candidate treatments for long COVID: a narrative review of expert and patient-driven priorities, 2026, Baptista, Glasziou+

    None of the details of the exercise trials are in the paper, so I wanted to check the supplementary material, but I can't find Appendix 1. I see a file called "Supplementary file 1.docx" which includes "Appendix A: Search terms for the living database", but it doesn't seem to have Appendix 1.
  18. forestglip

    O-Glycosylation patterns in Post-viral Fatigue Syndrome: Sialic Acid-preserving Chemical Release, 2025, de Otazo Hernández

    Several posts, starting from the following post, were moved to the thread: An Introduction to Common Misunderstandings and Controversies for Newcomers
  19. forestglip

    SequenceME genetic study - from Oxford Nanopore Technologies, the University of Edinburgh and Action for ME

    Health Rising: The Massive Sequence ME/CFS and Long COVID Project Aims to Find Precise Drivers of These Illnesses
  20. forestglip

    Evidence of White Matter Neuroinflammation in [ME/CFS]: A Diffusion-Based Neuroinflammation Imaging Study 2026 Yu et al

    I think Casterofspells meant to say "sedentary", suggesting that sedentary people would be lying down just as much.
Back
Top Bottom